<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02208882</url>
  </required_header>
  <id_info>
    <org_study_id>CV004-006</org_study_id>
    <nct_id>NCT02208882</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of BMS-986120 in Healthy Subjects and the Effect of BMS-986120 on the Pharmacokinetics of Midazolam in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and effect on Midazolam
      pharmacokinetics of multiple oral doses of BMS-986120 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability measured by number of subjects experience serious adverse events, deaths, adverse events leading to discontinuation, and potential clinically significant changes in electrocardiogram (ECG) parameters</measure>
    <time_frame>Up to 168 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability measured by percent of subjects experience serious adverse events, deaths, adverse events leading to discontinuation, and potential clinically significant changes in electrocardiogram (ECG) parameters</measure>
    <time_frame>Up to 168 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986120, BMT-141464, Midazolam, and 1`hydroxymidazolam</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-986120, BMT-141464, Midazolam, and 1`hydroxymidazolam</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to 24h [AUC(TAU)] of BMS-986120 and BMT-141464</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of the dosing Interval (Ctau) of BMS-986120 and BMT-141464</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T-HALF) of BMS-986120 and BMT-141464</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of BMS-986120, Midazolam, and 1`hydroxymidazolam</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC accumulation index (AI_AUC) of BMS-986120 and BMT-141464</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of AUC accumulation observed (T-HALFeff_AUC) of BMS-986120</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight [MR_AUC(TAU)] of BMT-141464</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax) of BMT-141464</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] of Midazolam and 1`hydroxymidazolam</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Midazolam and 1`hydroxymidazolam</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight [MR_AUC(INF)] of 1`hydroxymidazolam</measure>
    <time_frame>Part A (Days 1-8), Part B/C (Days 1-19), &amp; Part D (Days 1-22)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in protease-activated receptor-4 - agonist peptide (PAR4-AP) induced platelet aggregation of BMS-986120</measure>
    <time_frame>Part A (Days 1-3) &amp; Part B/C (Days 1-19)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Adult Volunteers</condition>
  <arm_group>
    <arm_group_label>Panel 1: BMS-986120 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986120 or Placebo multiple dose by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2: BMS-986120 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986120 or Placebo multiple dose by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 3: BMS-986120 or Placebo + Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986120 or Placebo (multiple dose) + Midazolam (single dose) by mouth as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 4: BMS-986120 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986120 or Placebo multiple dose by mouth as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986120</intervention_name>
    <arm_group_label>Panel 1: BMS-986120 or Placebo</arm_group_label>
    <arm_group_label>Panel 2: BMS-986120 or Placebo</arm_group_label>
    <arm_group_label>Panel 3: BMS-986120 or Placebo + Midazolam</arm_group_label>
    <arm_group_label>Panel 4: BMS-986120 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Panel 1: BMS-986120 or Placebo</arm_group_label>
    <arm_group_label>Panel 2: BMS-986120 or Placebo</arm_group_label>
    <arm_group_label>Panel 3: BMS-986120 or Placebo + Midazolam</arm_group_label>
    <arm_group_label>Panel 4: BMS-986120 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Panel 3: BMS-986120 or Placebo + Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          1. Healthy male and female subjects as determined by no clinically significant deviation
             from normal in medical history, physical examination, ECGs, and clinical laboratory
             determinations

          2. Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI=Weight (kg)/[Height(m)]2

          3. Women who are not of childbearing potential (i.e., who are postmenopausal or
             surgically sterile) and men, ages 18 to 75, inclusive

        Exclusion Criteria:

          1. Concurrent, or use within 2-weeks of study drug administration, of marketed or
             investigational, non-steroidal anti-inflammatory compounds (NSAIDS), aspirin or other
             antiplatelet agents, oral or parenteral anticoagulants

          2. Subjects at screening or prior to first dose with the following abnormal laboratory
             values upon repeat testing are excluded:

               -  i) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;upper
                  limit of normal (ULN)

               -  ii) Total bilirubin &gt;ULN, thyroid-stimulating hormone (TSH) &gt;1.5 x ULN with T4
                  within normal limits (Subjects with mild unconjugated hyperbilirubinemia due to
                  Gilbert's syndrome are excluded)

               -  iii) CK &gt;3 x ULN (unless exercise related and CK-MB within normal limits)

               -  iv) Activated partial thromboplastin (aPTT) or Prothrombin Time
                  (PT)/International Normalized Ratio (INR) &gt;ULN

               -  v) Blood urea nitrogen (BUN) or creatinine (Cr) &gt;ULN

          3. Hemoglobin or hematocrit or platelet count &lt;lower limit of normal (LLN)

          4. Bleeding time exceeding 8 minutes at pre-dose on Day -1

          5. Subjects with micro- or macro-hematuria and/or fecal occult blood detected during
             screening, baseline or documented during other recent medical assessment, unless
             deemed not clinically significant by the Investigator and Medical Monitor

          6. Any significant acute or chronic medical illness

          7. Current or recent (within 3 months of study drug administration) gastrointestinal
             disease

          8. Any major surgery within 12 weeks of study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ppd Development, Lp</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2014</study_first_submitted>
  <study_first_submitted_qc>August 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2014</study_first_posted>
  <last_update_submitted>July 3, 2015</last_update_submitted>
  <last_update_submitted_qc>July 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

